Taptap send 65m series capital series1/16/2024 Series: C Amount: $165 million Investors: Braidwell LP and TPG, Deerfield, Fairmount, Aisling Capital and an unnamed investor.īicara has bagged a $165 million series C just nine months after raising a $108 million series B. The MIT tech is designed to insert DNA sequences of any size into any programmed genomic location, combining the site-specificity of CRISPR/Cas9 with enzymes capable of inserting or writing sequences without needing double-strand DNA breaks. The programmable genomic integration company has launched with technology in-licensed from the Massachusetts Institute of Technology (MIT) and initial plans to develop gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases. Series: A & B Amount: $213 million Investors: Andreessen Horowitz (a16z) Bio + Health, ARCH Venture Partners, GV, Longwood Fund, Polaris Partners, Bruker Corporation, FUJIFILM Corporation, Alexandria Venture Investments and others. The company just launched chemistry, manufacturing, and control activities for EV-104 after preclinical data demonstrated robust anti-tumor efficacy in patient-derived solid tumor models. The Connecticut-based biotech plans to use the new funds to continue building out its platform and pipeline, which includes EV-104, EvolveImmune's lead multi-functional T-cell engager program. Series: N/A Amount: $37 million Investors: Pfizer Ventures, Solasta Ventures, and Takeda Ventures, Inc., and Bristol Myers Squibb.ĮvolveImmune has secured $37 million with support from the venture arms of several Big Pharmas. In tandem with the series B closure, the company has tapped Nassim Usman, Ph.D., to lead as president and CEO as co-founder, founding CEO and Chief Scientific Officer Neil Dhawan, Ph.D, transitions to the role of CSO and head of R&D. The biotech's mission is to discover and develop small molecule medicines using DNA-encoded covalent library tech combined with artificial intelligence/machine learning. The new money will go toward advancing Totus' clinical program, a mid-phase asset designed to treat PI3KCA mutant cancer, as well building out the rest of its pipeline and expanding its platform. Totus has closed the final tranche of a series B round totaling $66 million. Series: B Amount: $66 million Investors: DCVC Bio, North Pond Ventures, Camford Capital and the Regents of the University of Minnesota. Lassen unveiled in 2020 with $31 million with a goal of creating antibodies for cancer and fibrosis. Proceeds will go towards developing LASN01 in a phase 2 study for thyroid eye disease and to get LASN500 into investigational new drug enabling studies for cancer. Lassen is back with a series B financing that will help push the fibro-inflammatory disorder biotech's medicines through the clinic. Series: B Amount: $85 million Investors: Co-led by Frazier Life Sciences and Longitude Capital, plus BVF Partners, Catalio Capital Management, Alta Partners and Longwood Capital. CEO: Stig Hansen Series: A Amount: $55 million Investors: The Column Group, Dimension, Horizons Ventures and individual investorsĪfter Roche paid $2.7 billion upfront to acquire Carmot Therapeutics earlier this month, the biotech's spinoff Kimia has closed a $55 million series A. Launched in January 2023, Kimia will leverage Carmot’s Chemotype Evolution technology to which Kimia has a license outside the metabolic field. The new money will allow Kimia to build out its own platform and pursue a range of therapeutic targets in oncology, immunology and inflammation while continuing to partner with Carmot on certain metabolic programs.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |